Riskpilot← Back to searchSign inGet full accessSUND APOTEK AS
ASActiveOrg 895890162Skogsvågkrysset, 5382 SkogsvågRetail sale of pharmaceutical products · NACE 4773Est. 201017 employeeswww.apovest.no
Revenue 2024
NOK 22,5M
+4% vs 2023
EBITDA margin
-2.2%
+5% vs 2023
Equity ratio
-59.2%
Financial strength
Net profit 2024
NOK -648K
+6% vs 2023
| Revenue | NOK 22,5M | +4% |
| EBITDA | NOK -504K | +5% |
| Net profit | NOK -648K | +6% |
| Total assets | NOK 3,8M | -28% |
| Equity | NOK -2,3M | -40% |
| Employees | 17 | — |
Legal name
SUND APOTEK AS
Org number
895890162
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
2. september 2010
Share capital
NOK 100 000
Employees
17 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Eierskap og drift av apotek, handel med apotekvarer og relaterte produkter, aktuelle konsulent og rådgivningstjenester
Address
Skogsvågkrysset, 5382 Skogsvåg
Website
www.apovest.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 23 041 | 24 385 | 22 179 | 21 693 | 22 521 |
| Staff expenses | −3 984 | −4 251 | −4 523 | −4 076 | −3 863 |
| EBITDA | 817 | 71 | −1 237 | −528 | −504 |
| Depreciation & amort. | −95 | −63 | −91 | −151 | −149 |
| EBIT | 722 | 7 | −1 328 | −679 | −653 |
| Net financials | 0 | 2 | 0 | −7 | 5 |
| Profit before tax | 722 | 9 | −1 327 | −686 | −648 |
| Tax | 170 | −0 | −0 | −0 | −0 |
| Net profit | 552 | 9 | −1 327 | −686 | −648 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 091 | 10 361 | 6 061 | 5 307 | 3 804 |
| Equity | 398 | 408 | −919 | −1 605 | −2 253 |
| Long-term debt | 3 539 | 4 390 | 1 694 | 2 208 | 2 633 |
| Short-term debt | 4 154 | 5 563 | 5 286 | 4 704 | 3 423 |
| Total debt | 7 692 | 9 953 | 6 980 | 6 912 | 6 056 |
EBITDA margin
-2.2%
This company
15.8%
Market median
-114% vs market
20202024
Equity ratio
-59.2%
This company
38.2%
Market median
-255% vs market
20202024
Return on equity
-64758100.0%
This company
18.4%
Market median
-351946296% vs market
20202024
Net profit margin
-2.9%
This company
8.1%
Market median
-136% vs market
20202024
Asset turnover
5.92×
This company
1.12×
Market median
+429% vs market
20202024
Debt / equity
2.69×
This company
0.62×
Market median
-334% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TK Deputy Member | Deputy Member | 2025 |
JE Deputy Member | Deputy Member | 2010 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2010 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Mckesson Norway Holding As
SUND APOTEK AS Board members of SUND APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Terje Kvaal | Deputy Member | 0 companies |
| Jan Erik Helgemo | Deputy Member | 0 companies |
| Håvard Røkke | Chairman | 0 companies |